Smallpox Clinical Trial
Official title:
VHA Clinicians and Bioterror Events: Interactive Web-based Learning
Our 4-year project uses public domain software and content developed by a University of Alabama at Birmingham (UAB) team and updates, refines, and tailors it to the unique clinician populations and electronic educational applications of VAMCs We are testing an innovative, web-based intervention adapted specifically for the VA to increase syndromic recognition, treatment, and post-exposure prophylaxis of biological warfare agents at multiple VA sites via a randomized controlled trial (RCT). Ultimately, we will disseminate the intervention throughout the entire VA system.
Background:
Because of VA's long history in disaster preparedness, and the crucial role VA providers
will play, the VA medical system has the potential to make an enormous difference in
outcomes following a bioterror attack or infectious outbreak. A 2002 AHRQ report reviewed 60
studies and found that very few bioterrorism preparedness training programs were rigorously
evaluated. Our project was the first effort to formally test and implement a bioterrorism
preparedness intervention in the VA healthcare system. Because Internet-delivered
interventions have the potential for wide dissemination, we used the Internet to implement
the Intervention.
Objectives:
1. To develop, tailor, and continuously update and validate evidence- and scenario-based
electronic teaching and testing modules to increase VA clinicians' knowledge of
Category A biological warfare agents. We refer to these instruments as Bioterrorism
Case Analysis and Skills Enhancement Sessions (BioCASES) and Bioterrorism Skills Test
Sessions (BioTESTS).
2. To test the effectiveness of the BioCASES teaching modules by way of a randomized
controlled trial of VAMCs using the BioTESTS to evaluate their effectiveness for
increasing and sustaining VA clinician knowledge, skills, and ability to respond to
bioterrorism events.
3. To continue to develop and adapt BioCASES and BioTESTS for use in VA CME programs.
Ultimately, we will disseminate the intervention throughout the entire VA system.
Methods:
Our project team developed or refined and updated a total of 12 educational modules focusing
on CDC's Category A agents and other emerging infectious diseases. We developed post-test
instruments and case-based scenarios germane to the VA patient population for anthrax and
smallpox. Materials were designed specifically for the unique clinician populations and
electronic educational applications available in VAMCs. Website functionality and content
were refined using the nominal group technique and "thinking aloud" protocols. We tested our
innovative, web-based educational intervention at fifteen VA facilities via a randomized
controlled trial (RCT).
Status:
The intervention has been completed. Fifteen sites were randomized and completed the study
processes.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05976100 -
Study of the Safety, Tolerability, Pharmacokinetics of NIOCH-14 in Volunteers Aged 18-50 Years
|
Phase 1 | |
| Completed |
NCT01540929 -
Post-licensure Department of Defense (DOD) Screening Accuracy Study in Military Personnel
|
||
| Completed |
NCT00258947 -
Evaluation of Take and Safety of a Smallpox Vaccine in Healthy Young Adults
|
Phase 2 | |
| Completed |
NCT00189969 -
Take Rate, Immunogenicity and Safety of Elstree-BN Smallpox Vaccine in Healthy Vaccinia-Naive Subjects
|
Phase 1 | |
| Terminated |
NCT00053508 -
Dose Safety, Tolerability, and Immunogenicity of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination
|
Phase 2 | |
| Completed |
NCT01317238 -
Safety and Efficacy of CJ Smallpox Vaccine in Previously Vaccinated Healthy Volunteers
|
Phase 3 | |
| Completed |
NCT01056770 -
Safety and Efficacy of CJ Smallpox Vaccine in Healthy Volunteers
|
Phase 3 | |
| Terminated |
NCT00282581 -
Safety Study of MVA Smallpox Vaccine in HIV-positive Subjects Who Are Vaccinia Naive
|
Phase 1 | |
| Withdrawn |
NCT00389103 -
Safety Study of MVA Smallpox Vaccine in Subjects With a History of Atopic Dermatitis (AD)
|
Phase 1 | |
| Completed |
NCT00998543 -
A Long-Term Study of Healthy Adults Vaccinated With One Dose of Smallpox Vaccine (LISTER Strain)
|
Phase 2 | |
| Completed |
NCT00133575 -
ACAM 3000 MVA at Harvard Medical School
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT00103584 -
Safety and Immunogenicity Study of LC16m8, a Modified Smallpox Vaccine, in Healthy, Previously Unvaccinated Volunteers
|
Phase 1/Phase 2 | |
| Completed |
NCT00050505 -
Expanded Dryvax Dilution Study in Previously Vaccinated Adults
|
Phase 2 | |
| Completed |
NCT05846243 -
Study on Immunogenicity, Reactogenicity and Safety of the VACΔ6 Vaccine in Volunteers Aged 18-60 Years
|
Phase 2/Phase 3 | |
| Completed |
NCT05935917 -
Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults
|
Phase 1 | |
| Completed |
NCT00082446 -
Combination Study With MVA BN and Dryvax
|
Phase 1 | |
| Completed |
NCT00038987 -
Vaccinia Virus Vaccine (APSV) in Vaccinia- Naive Subjects: PILOT
|
Phase 1/Phase 2 | |
| Completed |
NCT05762523 -
Safety and Tolerability Study of the VAC∆6 Vaccine in Volunteers Aged 18-40 Years
|
Phase 1 | |
| Completed |
NCT04971109 -
Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Day
|
Phase 3 | |
| Completed |
NCT00646152 -
Poly-ICLC to Prevent Respiratory Viral Infections A Safety Study
|
Phase 1 |